In a report issued on August 2, Chris Parkinson from Mizuho Securities assigned a Buy rating to DuPont de Nemours (DD – Research Report), with a price target of $93.00. The company’s shares closed last Thursday at $58.57.
According to TipRanks.com, Parkinson is a 5-star analyst with an average return of 8.3% and a 58.2% success rate. Parkinson covers the Basic Materials sector, focusing on stocks such as Air Products and Chemicals, Sherwin-Williams Company, and Axalta Coating Systems.
DuPont de Nemours has an analyst consensus of Strong Buy, with a price target consensus of $75.15, representing a 29.1% upside. In a report issued on July 20, KeyBanc also maintained a Buy rating on the stock with a $82.00 price target.
Based on DuPont de Nemours’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.27 billion and net profit of $488 million. In comparison, last year the company earned revenue of $3.02 billion and had a net profit of $5.39 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Delaware-based DuPont de Nemours, Inc., which is commonly known as DuPont, is a multi-industry specialty solutions company and provides specialty materials, chemicals, and agricultural products in the United States, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa. The company was formed by the merger of Dow Chemical and E. I. du Pont de Nemours and Company on August 31, 2017. It operates through the following segments: Electronics & Imaging; Nutrition & Biosciences; Transportation & Industrial; Safety & Construction, and Non-Core.
Read More on DD:
- Mizuho Securities Sticks to Its Hold Rating for USA Compression (USAC)
- Analysts Are Bullish on These Utilities Stocks: Public Service Enterprise (PEG), Ovintiv (OVV)
- Skyworks Solutions (SWKS) Receives a Hold from Robert W. Baird
- Mizuho Securities Believes Arcutis Biotherapeutics (ARQT) Won’t Stop Here
- Skyworks Solutions (SWKS) Gets a Buy Rating from Rosenblatt Securities